Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.
Takeda was found to have entered into an anticompetitive agreement with generic drugmaker Par Pharma. Credit: Veroniksha/Shutterstock.com.
Takeda has been ordered to pay $885m – potentially rising to $2.5bn – after a landmark court case verdict found the Japanese pharma company liable for a conspired arrangement to keep market monopoly of its constipation drug Amitiza (lubiprostone).
A jury in the US District Court for the District of Massachusetts found Takeda liable in a pay-for-delay litigation. This anticompetitive tactic involves a pharmaceutical company paying a generic rival to hold off marketing a copycat drug in return for financial compensation. It is the first time a federal jury has found a drugmaker liable in a pay-for-delay case. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
